A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Trial Profile

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary)
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 30 Sep 2015 According to a Galenica Group media release, the New Drug Application (NDA) for sucroferric oxyhydroxide in the treatment of hyperphosphatemia has been approved by the Ministry of Health, Labour and Welfare in Japan.
    • 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top